Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen (AMGN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 115,880,744
  • Shares Outstanding, K 745,000
  • Annual Sales, $ 21,662 M
  • Annual Income, $ 6,939 M
  • 36-Month Beta 1.14
  • Price/Sales 5.14
  • Price/Book 3.77

Price Performance

See More
Period Period Low Period High Performance
1-Month
145.12 +5.98%
on 12/22/16
161.00 -4.47%
on 01/06/17
+6.06 (+4.10%)
since 12/19/16
3-Month
133.64 +15.09%
on 11/04/16
163.35 -5.85%
on 10/20/16
-7.28 (-4.52%)
since 10/19/16
52-Week
133.64 +15.09%
on 11/04/16
176.85 -13.03%
on 09/23/16
+2.50 (+1.65%)
since 01/19/16

Most Recent Stories

More News
Can Amgen (AMGN) Be a Top Choice for Value Investors?

Let's see if Amgen Inc. (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.

OilPrice.com: This Could Be the Biggest Winner of 2017's Biotech Boom

OilPrice.com Market Commentary: The catalysts for a major biotech rally in 2017 are already multiplying-not least because of the Trump presidential victory-and one little-known company is poised for huge...

4 Top Biotech Mutual Funds for 2017

Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance

deCODE Study Shows that Variants in the Sequence of the Genome that Contribute to Educational Attainment are Under Negative Selection

In a study published today, scientists at deCODE genetics use genomic and genealogical data from across the population of Iceland over many decades to show that people who carry sequence variations linked...

OilPrice.com: Life-Saving Device Could Transform the Medical Market in 2017

OilPrice.com Market Commentary: A little-known biotech company is poised to potentially earn millions in revenue with the planned upcoming release of a breakthrough technology that could prevent massive...

Research and Markets - Global Protein Therapeutics Market to Grow 7% by 2021: Product Type, Therapy Area & Protein Function - Key Vendors are AbbVie, Amgen & Merck

DUBLIN, Jan 13, 2017 /PRNewswire/ --

Research and Markets - Global Protein Therapeutics Market to Grow 7% by 2021: Product Type, Therapy Area & Protein Function - Key Vendors are AbbVie, Amgen & Merck

Research and Markets has announced the addition of the "Global Protein Therapeutics Market 2017-2021" report to their offering.

Coherus Offers Positive Phase III Data on Humira Biosimilar

Coherus BioSciences, Inc. (CHRS) reported encouraging top-line data from an ongoing part 3, of a phase III study on its biosimilar version of AbbVie Inc.'s (ABBV) Humira (adalimumab), CHS-1420, for the...

Trump Attacks Biotech & Pharma: ETFs Bleed

Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.

Trump Attacks Biotech & Pharma: ETFs Bleed

Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Support & Resistance

2nd Resistance Point 156.69
1st Resistance Point 155.24
Last Price 153.80
1st Support Level 152.80
2nd Support Level 151.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.